Artificial intelligence in human health and life sciences is transforming the delivery of healthcare.
Analysts are predicting that the AI health market will be over $6.5 billion by 2020 — a staggering annual compound growth rate of 40%. The amount of available digital data is doubling every two years — from nearly 4.5 trillion gigabytes in 2013 to 44 trillion gigabytes by 2020.
This combination of data availability and AI advancement will present opportunities for things like drug discovery and creation, treatment plan design, healthcare workflow optimization, image analysis automation, and medication management and adherence improvements.
Join us as multinational corporations discuss their views on adoption, use and deployment of AI; entrepreneurs present what’s being developed now and what will be possible in the future; and investors explore “reality versus bubble” and the evolving AI investment landscape.
Who should attend?
Get an inside look at how other investors are navigating AI and health investing. You’ll also have the opportunity to meet successful health and AI companies — both startups and corporations.
Hear from promising health startups that are integrating AI, and network with corporations and investors who are interested in the health and AI sector.
Meet the health and AI community and connect with startups, companies, students and investors working in the health and AI sector.
Find out what’s happening at the intersection of AI and healthcare, and connect with other industry players — from startups and corporations to investors.
1:30 p.m.: Registration
2:00 p.m.: Opening Remarks – Ying Tam, Managing Director, Health Venture Services, MaRS
2:10 p.m.: Corporates Embracing AI: How are big companies planning for AI? We’ll cover whether companies are building or buying and what the long term vision and strategy is for AI in the marketplace.
- Dr. Peter Grandsard, Executive Director of Research, Amgen
- Nathalie Le Prohon, Vice President, Healthcare Industry, IBM Canada
- Peter Jones, Healthcare Industry Lead, Microsoft
- Azam Khan, Complex Systems Group, Autodesk Research
2:55 p.m.: Venture Talks: How to seize the AI opportunity. Where are ventures going with AI and what trends are ahead?
- Liam Kaufman, CEO & Founder, WinterLight Labs
- Carlo Perez, Founder & CEO, Swift Medical
- Dr. Shyam Ramchandani, VP Research & Development, Analytics 4 Life
- Naheed Kurji, President & CEO, Cyclica Inc.
- Dr. Shelley Boyd, President & CEO, Tracery
3:45 p.m.: Networking break
4:15 p.m.: Venture Capital Firms Navigating AI: What’s happening with AI and health investing? We’ll explore who is doing what, the investment thesis, and whether the AI boom is a bubble or reality.
- James Hardiman, Partner, Data Collective
- Dusan Perovic, VP, Two Sigma Ventures
- Julia Geer, Head of Growth, Innovation and Incubation, Siemens Healthineers
- Peter Van Der Velden, Managing General Partner, Lumira Capital
5:00 p.m.: Closing remarks
Nathalie Le Prohon
Nathalie is Vice President, Healthcare Industry at IBM Canada. She rejoined IBM in 2016 to lead a national team of industry professionals dedicated to working with clients in their healthcare transformation journey. In November 2017, she also received responsibilities for the telecommunication industry including the media and entertainment sectors. Having successfully battled breast cancer twice, […]
As Healthcare Industry Lead for Microsoft Canada, Peter Jones develops the strategy vision of modern healthcare for the Canadian marketplace. Working closely with the Microsoft Worldwide Healthcare team, Peter is deeply enriched in the best practices of healthcare digital transformation that is being practiced by healthcare industry leaders around the globe. Peter’s mandate is to […]
Julis is Head of Growth, Innovation and Incubation at Siemens Healthineers. She has over 15 years of experience in a variety of healthcare roles in organizations ranging from early stage startup to large Fortune 100 companies. She has led efforts for both niche and enterprise IT product lines, medical devices and first in class pharmaceutical […]
Carlo Perez is founder and CEO of Swift Medical. He is an engineer and entrepreneur, passionate about delivering designs and transformative technologies that put empathy into action. Before he set out as an entrepreneur, he spent seven years in R&D at Advanced Micro Devices (AMD) Inc., where his research focused on industry-leading 3D graphics hardware. […]
Azam is head of the Complex Systems Group at Autodesk Research. He is also the founder of the Parametric Human Project Consortium, SimAUD: the Symposium on Simulation for Architecture and Urban Design, and the CHI Sustainability Community. He is also a founding member of the International Society for Human Simulation and has been the Velux […]
Liam is the cofounder and CEO of WinterLight Labs, which uses speech and machine learning to detect Alzheimer’s disease. Liam has conducted research in cognitive neurology focusing on mapping motor areas with functional magnetic resonance imaging (fMRI) and analyzing pre-surgical fMRI brain mapping data. Liam completed a BSc in Computer Science and an MSc in […]
Analytics 4 Life
Dr. Ramchandani is VP of research and development at Analytics 4 Life (A4L). He has been with A4L since its inception and through his over six years has served in operations, business development, marketing and clinical and currently leads the R&D team. Shyam has been involved with early stage medically-oriented companies through his entire career. […]
Dr. Shelley Boyd
Dr. Boyd is founding President and CEO of Tracery Ophthalmics and founding President and CSO of Translatum Medicus. As a clinician-scientist at St Michael’s Hospital, she oversees the Walter Retinal Research Laboratory. Shelley was formerly head of the Ocular Angiogenesis Research Program for Novartis during the diligence, in-licensing and early development of Lucentis® with Genentech, […]
Two Sigma Ventures
Dusan directs Two Sigma Ventures’ investing efforts at the intersection of life science, healthcare and data science. He joined Two Sigma in 2007 to work on company growth strategy, and he has since helped the firm launch several new business units. Dusan also worked with research groups across the firm in discovering and evaluating new […]
Dr. Peter Grandsard
Dr. Grandsard is Executive Director of Research, Amgen, where he is responsible for the characterization of pre-clinical therapeutic candidates. Since joining Amgen in 1996, he has had a variety of roles and responsibilities. Trained as a chemical engineer (BE/ME) and as an analytical chemist (Ph.D.), he started as a scientist designing and implementing new laboratory […]
Naheed is President and CEO of Cyclica Inc., a Toronto-based life sciences technology company. He leads the team delivering the next step in cloud-based drug discovery. Cyclica has innovated a novel cloud-based and AI-augmented platform, Ligand Express, that is being used by scientists in the pharmaceutical industry to more efficiently discover better medicines. Naheed focuses […]
James is Partner at Data Collective, where he invests in deep technologies that are transforming industries. Prior to that, James was a consultant at ZS and advised both Fortune 50 and pre-revenue healthcare and biotech companies on their sales and marketing strategy. James also worked with technology executives during a stint in the Blackstone Group’s […]
Peter van der Velden, Lumira Capital
Peter is the managing general partner of Lumira Capital, Canada’s largest and most active dedicated healthcare venture capital investor. For the past 28 years, Peter has been deeply engaged in Canada’s innovation ecosystem as an operator, investor, service provider and mentor. He is a very active volunteer, a frequent lecturer and is on the board […]